

Table 1: Drug-resistance mutations seen in genital secretions and plasma

	Treatment			HIV RNA copies/ml		NRTI and NNRTI resistance mutations			PI resistance mutations		
	Group	First-line regimen	Second-line regimen	at week 96		at week 96		at week 0	at week 96		at week 0
				Cervico-Vaginal Samples	Plasma	Cervico-Vaginal Samples	Plasma	Plasma	Cervico-Vaginal Samples	Plasma	Plasma
1	bPI/RAL	FTC TDF NVP	LPV/r RAL	242	<40	K65R, Y181C, M184V, K219E	Testing not applicable	K65R, Y181C, M184V, K219E	No Mutations	Testing not applicable	No Mutations
2	bPI/NRTI	3TC ZDV NVP	3TC TDF LPV/r	1,330	<40	M41L, A98G, M184V, G190A, L210W, T215Y	Testing not applicable	M41L, M184V, G190A, L210W, T215Y	No Mutations	Testing not applicable	No Mutations
3	bPI/NRTI	3TC ZDV NVP	3TC TDF LPV/r	164	<40	D67N, K70R, A98G, M184V, G190A, T215Y	Testing not applicable	D67N, K70E, K70R, F77L, F116Y, Q151M, M184V, G190A, L210W,	K20R	Testing not applicable	No Mutations
4	bPI/NRTI	3TC ZDV NVP	DDI ABC LPV/r	124	<40	M41L, A98G, Y181C, M184V, L210W, T215Y, H221Y	Testing not applicable	M41L, Y181C, M184V, L210W, T215Y, V108L, H221Y	No Mutations	Testing not applicable	No Mutations
5	bPI mono	3TC TDF NVP	LPV/r	907	20,748	No Mutations	No Mutations	Not tested	M46L, I54V, V82A	No Mutations	Not tested
6	bPI mono	3TC ZDV NVP	LPV/r	60	297	No Mutations	Testing not applicable	Not tested	No Mutations	Testing not applicable	Not tested

Note: FTC=emtricitabine, TDF=tenofovir, NVP=nevirapine, 3TC=lamivudine, ZDV=zetidovudine, LPV/r = ritonavir-boosted lopinavir, RAL=raltegravir, DDI=didanosine, ABC=abacavir. Resistance testing was performed in all genital secretions samples with a VL>40 copies/ml; and in plasma samples with VL>400 copies/ml at baseline (except those randomised to PI monotherapy) and at week 96.